Yükleniyor... / Loading...
This study investigated the person-to-person variability (pharmacokinetics) in the body's levels of Sunitinib in patients with metastatic renal cancer. Blood samples were collected from participants for genetic analysis and drug-level measurement. It was a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * The patient was correctly informed concerning the implementation of the study, its objectives, constraints and patient rights * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient has kidney cancer and should begin treatment with sunitinib (Sutent) at the time of inclusion Exclusion Criteria: * The patient started treatment with sunitinib (Sutent) before inclusion * The patient is participating in another interventional study * The patient has participated in another interventional study within the last month * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * The patient has a contraindication (or an incompatible drug combination) for a treatment used in this study